This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

The content of this website has been produced in line with the BOSULIF®▼ (bosutinib) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BOSULIF Prescribing Information for Great Britain and for Northern Ireland, and adverse event reporting information can be found at the bottom of the page.

Safety data

A well defined and manageable safety profile1,2

<1% of the overall patient population discontinued due to diarrhoea

y-axis: AE, x-axis: patients, %

*Patients who received one or more doses of study drug for either newly diagnosed CP CML or were resistant or intolerant to prior therapy with CP, AP, BP CML or Ph+ ALL. 
The data shown includes real-world data in addition to safety data from the BFORE trial and Study 200.

No new cardiac or vascular safety signals at 24 months in newly diagnosed patients3​​​​​​​

Safety events for study population exposed to bosutinib/imatinib

*Patients who received one or more doses of study drug.

Further information

Please refer to the BOSULIF SmPC for full details of adverse events

If you still require further information, please contact Medical Information

BOSULIF SmPC Medical Information

Explore more

Perspectives in Managing CML

Hear views from the MDT: Rebecca Hallam (nurse) and Andrea Preston (pharmacy) on how to support patients through their treatment

Learn more

** This is an optional area where footnotes can live.

New challenges: long-term TKI therapy

Hear Dr. Alex Lyon’s views on long-term TKI treatment in an ageing patient population video

Learn more

** This is an optional area where footnotes can live.


AE, adverse event; ALL, acute lymphoblastic leukaemia; ALT, alanine aminotransferase; AP, accelerated phase; AST, aspartate aminotransferase; BP, blast phase; CML, chronic myeloid leukaemia; CP, chronic phase; MDT, Multi-Disciplinary Team; Ph+, Philadelphia chromosome-positive; SmPC, Summary of Product Characteristics.
 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
References:
  1. BOSULIF Summary of Product Characteristics for Great Britain click here. BOSULIF Summary of Product Characteristics for Northern Ireland click here.
  2.  Hochhaus A, et al. Leukemia 2020;34:2125–2137.
  3. Cortes et al. Presented at American Society of Clinical Oncology Annual Meeting, 2018; Oral presentation 7002
PP-BOS-GBR-1319. September 2021

If you are seeking answers that are not on this page, can Medical Information help?

Click here

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No